Lidocaine metabolism (Homo sapiens)
From WikiPathways
Description
Lidocaine is primarily metabolized by CYP1A2 but minor involvement of CYP3A4 is observed too. Based on [KEGG](http://www.genome.jp/kegg-bin/show_pathway?hsa00982).
Quality Tags
Ontology Terms
Bibliography
- Isohanni MH, Neuvonen PJ, Olkkola KT; ''Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine.''; Basic Clin Pharmacol Toxicol, 2006 PubMed Europe PMC Scholia
- Wang JS, Backman JT, Wen X, Taavitsainen P, Neuvonen PJ, Kivistö KT; ''Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.''; Pharmacol Toxicol, 1999 PubMed Europe PMC Scholia
- Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P; ''Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function.''; Clin Pharmacol Ther, 2004 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
View all... |
Name ![]() | Type ![]() | Database reference ![]() | Comment ![]() |
---|---|---|---|
2,6-xylidine | Metabolite | CHEBI:28738 (ChEBI) ![]() | |
2-amino-3-methylbenzoate | Metabolite | 4161142 (PubChem-compound) ![]() | |
3-hydroxylidocaine | Metabolite | 161824 (PubChem-compound) ![]() | |
3-hydroxymonoethyl glycinexylidide | Metabolite | C16572 (KEGG Compound) ![]() | |
4-hydroxy- 2,6-dimethylaniline | Metabolite | CHEBI:55545 (ChEBI) ![]() | |
CYP1A2 | GeneProduct | ENSG00000140505 (Ensembl) ![]() | |
CYP3A4 | GeneProduct | ENSG00000160868 (Ensembl) ![]() | |
Lidocaine | Metabolite | HMDB0014426 (HMDB) ![]() | |
glycinexylidide | Metabolite | CHEBI:357241 (ChEBI) ![]() | |
monoethyl glycinexylidide | Metabolite | 24415 (PubChem-compound) ![]() |
Annotated Interactions
No annotated interactions